PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY
A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION
A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA
Non-Comparative, Two-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab *BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous Stem Cell Transplant (ASCT)
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone for the Treatment of Multiple Myeloma
A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) EITHER AS MONOTHERAPY OR IN COMBINATION WITH POMALIDOMIDE (POM) WITH OR WITHOUT LOWDOSE DEXAMETHASONE (DEX) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma
A phase 1, open-label, dose-escalation study of SGN-CD19B in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
